Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Informed Consent Psychotropic topic
No spam. Unsubscribe anytime.
Psychotropic informed‑consent bill fails after emotional testimony and clinical concerns
Summary
HB 1160, which would have required providers to give FDA product labeling and obtain signed acknowledgments for psychotropic prescriptions, failed in the House Health Subcommittee after public testimony highlighted suicide‑risk data and clinicians raised practical barriers to implementation.
House Bill 1160, sponsored in subcommittee by Representative Lynn, failed on an 3–5 vote after more than an hour of public testimony and clinical questioning.
Public witnesses urged the committee to require that patients receive FDA product labels and sign an acknowledgment when prescribed psychotropic medications. Bernadette Pager, who said she is the Tennessee volunteer director of Stand For All Freedom and a private citizen, told the committee: "We don't intend to stop any prescriptions. We just wanna make sure that individuals who do choose these drugs and choose them for their children have the information they need so that they can then recognize adverse events when they happen." Britney Ruiz, volunteer director of policy for CCHR Tennessee, cited state statistics she said show youth suicides rose 47% from 2019 to 2023 and asserted "1 in 12 children and 1 in 4 adults are on psychotropic medications through TennCare."
Dr. Michelle Cochran, a Nashville psychiatrist who identified herself as president and chief medical officer of Synaptic Psych and a representative of physician groups, told the committee that while informed consent is important, the bill as drafted creates barriers to care. She warned of telehealth and electronic‑medical‑record limits, difficulties distributing and signing lengthy FDA documents, and risks that some prescribers might stop offering medications rather than manage the new administrative burden. "I worry what's gonna happen is that 0.6666666666666667 of psychotropic medications that are prescribed by pediatricians, primary care doctors and O.B.‑G.Y.N.s are going to stop because they're going to see this too difficult," she said.
Committee members questioned how the requirement would work for telehealth visits, who would bear liability if a patient refused to sign, and whether the statutory language referred to the full package insert or the FDA highlights page. Representative Lynn said the bill includes a declination provision so patients can refuse acknowledgment and that the bill contemplates the FDA highlights page rather than the full insert. Chairman Williams acknowledged the amendment "dramatically improves the original bill" but said he remained unconvinced the current language was workable. The subcommittee voted 3–5 and the measure failed to advance.
The bill's failure leaves the underlying questions intact: how to balance patient information and clinical workflow, how to implement any new paperwork in telehealth and low‑resource settings, and whether alternative approaches (standardized highlight pages or state templates) can achieve the sponsors' objectives without impairing care.
